CML clonal evolution with resistance to single agent imatinib therapy

R. Swords, J. Quinn, M. Fay, R. O'Donnell, J. Goldman, P. T. Murphy

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

We describe a 58-year-old male diagnosed with chronic myeloid leukaemia (CML) who failed to have a cytogenetic response to interferon-α and hydroxyurea. On subsequent therapy with imatinib mesylate he failed to have any cytogenetic response but also developed a complex clonal evolution with an additional Philadelphia (Ph) chromosome and trisomy 8 respectively in two Ph-positive subclones. The addition of cytosine arabinoside to imatinib resulted in reversion to single Ph-chromosome positivity with the disappearance of the previous additional clonal abnormalities. The case demonstrates the efficacy of combined treatment with imatinib and cytarabine in the management of CML resistant to single agent imatinib.

Original languageEnglish (US)
Pages (from-to)347-349
Number of pages3
JournalClinical and Laboratory Haematology
Volume27
Issue number5
DOIs
StatePublished - Oct 1 2005

Keywords

  • Chronic myeloid leukaemia
  • Clonal evolution
  • Imatinib
  • Philadelphia chromosome
  • Resistance

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'CML clonal evolution with resistance to single agent imatinib therapy'. Together they form a unique fingerprint.

  • Cite this

    Swords, R., Quinn, J., Fay, M., O'Donnell, R., Goldman, J., & Murphy, P. T. (2005). CML clonal evolution with resistance to single agent imatinib therapy. Clinical and Laboratory Haematology, 27(5), 347-349. https://doi.org/10.1111/j.1365-2257.2005.00721.x